This study is active but not recruiting. It focuses on bipolarity and currently lists study information in France.
This observational study is following people with bipolarity to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment. This study may not offer a new treatment, and its main value is helping researchers learn from follow-up information that may improve future care.
The official record suggests in-person participation through a hospital, with sites including Néphrologie, Hôpital Henri-Mondor in Créteil and Physiologie Explorations fonctionnelles multidisciplinaires, Hôpital Bichat in Paris. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually meeting the main study requirements, while common reasons not to take part include pregnancy or breastfeeding and other factors that could make participation unsuitable. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
This study may matter because it is evaluating Anhydrous Amiloride Hydrochloride, Placebo in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in France.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Assistance Publique - Hôpitaux de Paris. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is Phase 4. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.